Apixaban 2,5mg or 5mg Pfizer Film-Coated Tablets
PDF Leaflet Revision Date: 11 July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of VTE and stroke in NVAF.
Dosage (summary)
2.5 mg twice daily for VTE prevention; 5 mg twice daily for NVAF.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended in pregnancy; avoid breastfeeding.
Key Drug Interactions
- Strong CYP3A4 and P-gp inhibitors
- Strong CYP3A4 and P-gp inducers
- NSAIDs
Contraindications
- Hypersensitivity
- Active bleeding
- Severe renal disease
- Severe hepatic disease
Common side effects
- Haemorrhage
- Contusion
- Epistaxis
- Haematoma
Counselling Points
- Take with or without food
- Monitor for signs of bleeding
- Do not crush tablets for certain patients
Serious warnings
- Risk of bleeding
- Use with caution in high-risk patients
Important Disclaimer
The Apixaban 2,5mg or 5mg Pfizer Film-Coated Tablets professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
